STOCK TITAN

Innate Pharma S.A. (IPHA) Financials

IPHA NASDAQ
FY2025 annual
Revenue $10.6M -55.2% YoY (EUR)
Net Income -$57.7M n/m YoY (EUR)
EPS (Diluted) -$0.65 n/m YoY (EUR)
Free Cash Flow -$62.1M n/m YoY (EUR)
Market Cap $105.0M as of Nov 19, 2026
Price / Sales 9.9x on $10.6M revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book n/m negative shareholder equity, so no book multiple, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD, translated from EUR FYE December

Amounts are shown in US dollars, translated from EUR at the rate recorded for each period. Growth rates marked (EUR) are measured in EUR, the currency the company reports in, so a move in the exchange rate does not count as growth.

Newest figures come from the 20-F for FY2025, filed Apr 1, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IPHA SEC filings page.

Innate Pharma S.A. (IPHA) reported $10.6M in revenue for fiscal year 2025, down 55.2% in EUR terms from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Rhea AI IPHA FY2025

The business remains development-stage: research spending dwarfs revenue, while cash losses are eroding the balance sheet.

In FY2025, operating cash flow of -$61.9M nearly matched free cash flow of -$62.1M, showing that the cash drain comes from core operations rather than heavy capital spending. With R&D at 484.4% of revenue and capital expenditures at just 1.6%, the company is funding development activity, not building a capital-intensive operating base.

Revenue fell to $10.6M in FY2025 while R&D remained $51.2M, creating a mismatch that kept the net loss at $57.7M despite lower R&D than FY2024. The model therefore still depends on development investment far exceeding internally generated revenue.

FY2025 liabilities of $99.1M exceeded assets of $73.6M, leaving negative equity of -$25.5M. The current ratio also fell from 2.6x in FY2024 to 1.3x, indicating materially less short-term balance-sheet flexibility alongside the negative equity position.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 45 / 100
Financial Health Score (4 of 6 dimensions) 45/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Innate Pharma S.A.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
n/a

Not available for Innate Pharma S.A., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.

Dilution
61

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Innate Pharma S.A. scores 61/100 on it among other emerging companies.

R&D Intensity
88

Innate Pharma S.A. spent $51.2M on research and development in fiscal year 2025, which was 69.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Innate Pharma S.A. scores 88/100 among other emerging companies.

Revenue Progress
2

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Innate Pharma S.A. scores 2/100 on it among other emerging companies.

Burn Trend
28

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Innate Pharma S.A. scores 28/100 on it among other emerging companies.

Balance Sheet
n/a

Not available for Innate Pharma S.A., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.

Piotroski F-Score Partial
0/7

Innate Pharma S.A. passes 0 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Innate Pharma S.A. reported a net loss of $57.7M while operations used $61.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Innate Pharma S.A. reported an operating loss of $63.4M against $516K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$10.6M
YoY (EUR)-55.2%
5Y CAGR (EUR)-33.6%

Innate Pharma S.A. generated $10.6M in revenue in fiscal year 2025. This represents a decrease of 55.2% in EUR terms from the prior year.

EBITDA
-$61.8M
YoY (EUR)n/m

Innate Pharma S.A.'s EBITDA was -$61.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.

Net Income
-$57.7M
YoY (EUR)n/m
5Y CAGR (EUR)n/m

Innate Pharma S.A. reported a net loss of $57.7M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

EPS (Diluted)
-$0.65
YoY (EUR)n/m
5Y CAGR (EUR)n/m

Innate Pharma S.A. earned -$0.65 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$62.1M
YoY (EUR)n/m
5Y CAGR (EUR)n/m

Innate Pharma S.A. recorded an outflow of $62.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.

Cash & Debt
$33.0M
YoY (EUR)-57.7%
5Y CAGR (EUR)-27.1%

Innate Pharma S.A. held $33.0M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.

Shares Outstanding
94M
YoY+11.8%
5Y CAGR+3.5%

Innate Pharma S.A. had 94M shares outstanding in fiscal year 2025. This represents an increase of 11.8% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending
$51.2M
YoY (EUR)-16.1%
5Y CAGR (EUR)-2.6%

Innate Pharma S.A. invested $51.2M in research and development in fiscal year 2025. This represents a decrease of 16.1% in EUR terms from the prior year.

Capital Expenditures
$164K
YoY (EUR)-64.2%
5Y CAGR (EUR)-31.2%

Innate Pharma S.A. invested $164K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 64.2% in EUR terms from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

IPHA Income Statement

Figures in USD, translated from EUR at the rate recorded for each period, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IPHA annual income statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
Revenue$10.6M-55.2%$20.8M-67.4%$68.2M+6.9%$61.7M+133.5%$28.0M-64.6%$85.3M-18.3%$95.9M-9.1%$107.6M+113.4%$52.9M
R&D Expenses$51.2M-16.1%$53.8M-7.2%$62.0M+8.4%$55.3M+9.9%$53.2M-5.4%$60.8M-21.0%$70.6M-9.6%$79.7M+3.8%$80.5M
Operating Income-$63.4Mn/m-$53.4Mn/m-$14.0Mn/m-$61.4Mn/m-$54.1M-4532.3%$1.3M-31.5%$1.8M-69.4%$5.9Mn/m-$48.1M
EBITDA-$61.8Mn/m-$51.3Mn/m-$8.4Mn/m-$12.9Mn/m-$48.9M-174.7%$70.8M+219.7%$20.3M+44.3%$14.4Mn/m-$42.8M
Interest Expense$516K-22.3%$586K-11.6%$708K+122.2%$308K-7.7%$353K-8.5%$417K+67.2%$229K+100.0%$117K-9.7%$136K
Income Tax$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m-$381K-190.5%$442K
Net Income-$57.7Mn/m-$51.2Mn/m-$8.4Mn/m-$62.2Mn/m-$59.8Mn/m-$78.3Mn/m-$23.3M-780.8%$3.5Mn/m-$58.2M
EPS (Basic)-$0.65n/m-$0.63n/m-$0.10n/m-$0.78n/m-$0.75n/m-$0.99n/m-$0.35-719.7%$0.06n/m-$1.07
EPS (Diluted)-$0.65n/m-$0.63n/m-$0.10n/m-$0.78n/m-$0.75n/m-$0.99n/m-$0.35-719.7%$0.06n/m-$1.07

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses, Diluted Shares (Avg).

IPHA Balance Sheet

Figures in USD, translated from EUR at the rate recorded for each period, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IPHA annual balance sheet
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
Total Assets$73.6M-43.5%$115.0M-36.6%$193.8M-12.1%$213.2M-25.5%$302.8M-13.0%$376.0M-23.4%$450.6M-11.0%$516.9M+76.9%$306.6M
Current Assets$54.8M-45.5%$88.8M-42.1%$163.7M+5.9%$149.6M+1.1%$156.5M-20.3%$212.1M-27.0%$266.8M-25.7%$366.2M+132.4%$165.3M
Cash & Equivalents$33.0M-57.7%$68.7M-6.0%$78.1M-16.2%$90.1M-18.8%$117.4M-24.2%$167.3M-32.6%$227.8M+33.2%$174.5M+53.3%$119.5M
Accounts Receivable$14.6M+149.4%$5.1M-91.1%$61.5M+44.9%$41.0M+108.2%$20.8M-15.6%$26.7M+16.4%$21.0M-87.7%$174.3M+610.4%$25.7M
Total Liabilities$99.1M-17.4%$105.8M-17.1%$136.4M-15.1%$155.3M-9.3%$181.2M+5.7%$185.2M-17.7%$206.5M-35.3%$325.5M+82.6%$187.0M
Current Liabilities$43.0M+11.1%$34.1M-16.8%$43.8M-4.1%$44.2M-48.3%$90.4M+75.6%$55.6M-62.7%$136.8M-38.1%$225.4M+166.2%$88.9M
Non-Current Liabilities$56.1M-31.0%$71.7M-17.2%$92.5M-19.4%$111.1M+29.5%$90.7M-24.3%$129.6M+70.6%$69.7M-28.8%$99.9M-8.3%$114.4M
Total Equity-$25.5M-345.7%$9.1M-83.0%$57.4M-4.2%$57.9M-49.6%$121.6M-31.1%$190.8M-28.3%$244.1M+30.1%$191.5M+68.1%$119.6M
Retained EarningsN/AN/AN/AN/AN/AN/A-$151.5Mn/m-$159.2Mn/m-$124.5M

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.

IPHA Cash Flow Statement

Figures in USD, translated from EUR at the rate recorded for each period, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IPHA annual cash flow statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
Operating Cash Flow-$61.9Mn/m-$7.1Mn/m-$36.0Mn/m-$20.5Mn/m-$66.2Mn/m-$63.3M-248.2%$39.2Mn/m-$37.3Mn/m-$57.8M
Depreciation & Amortization$1.6M-30.6%$2.1M-60.8%$5.6M-88.8%$48.6M+887.9%$5.2M-91.9%$69.5M+243.6%$18.6M+123.3%$8.5M+68.5%$5.3M
Capital Expenditures$164K-64.2%$405K+11.4%$388K-34.4%$572K-42.4%$1.1M+2.4%$1.1M-28.6%$1.4M+45.6%$1.0M-70.5%$3.6M
Free Cash Flow-$62.1Mn/m-$7.5Mn/m-$36.4Mn/m-$21.1Mn/m-$67.2Mn/m-$64.4M-256.5%$37.8Mn/m-$38.3Mn/m-$61.3M
Investing Cash Flow$8.6M-20.8%$9.5M-55.4%$22.8M+999.1%$2.0Mn/m-$1.0Mn/m-$16.4Mn/m-$69.7M-355.9%$27.8Mn/m-$35.4M
Financing Cash Flow$7.1Mn/m-$6.2Mn/m-$2.2Mn/m-$2.0M-106.8%$30.4Mn/m-$1.4M-101.5%$87.3M+27.0%$70.1M+6590.9%$1.1M

Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.

IPHA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IPHA annual financial ratios
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
Operating Margin-599.8%-256.3%-20.5%+79.0pp-99.6%-193.6%1.6%-0.3pp1.8%-3.6pp5.5%+96.3pp-90.8%
Net Margin-546.1%-245.9%-12.3%-100.7%-213.8%-91.7%-67.4pp-24.3%-27.5pp3.3%-109.9%
Return on EquityN/A-560.0%-545.4pp-14.6%+92.7pp-107.3%-58.1pp-49.1%-8.1pp-41.0%-31.5pp-9.6%-11.4pp1.8%+50.5pp-48.7%
Return on Assets-78.4%-33.9pp-44.5%-40.2pp-4.3%+24.8pp-29.1%-9.4pp-19.7%+1.1pp-20.8%-15.6pp-5.2%-5.9pp0.7%+19.7pp-19.0%
Current Ratio1.27-1.3x2.60-1.1x3.73+0.4x3.38+1.7x1.73-2.1x3.81+1.9x1.95+0.3x1.62-0.2x1.86
Liabilities-to-EquityN/A11.57+9.2x2.38-0.3x2.68+1.2x1.49+0.5x0.97+0.1x0.85-0.9x1.70+0.1x1.56
Asset Turnover0.140.0x0.18-0.2x0.35+0.1x0.29+0.2x0.09-0.1x0.230.0x0.210.0x0.210.0x0.17
FCF Margin-587.4%-36.2%+17.2pp-53.4%-19.3pp-34.1%-240.4%-75.5%-114.9pp39.4%+74.9pp-35.5%-115.9%

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$25.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Innate Pharma S.A. IPHA FY2025 $10.6M -$57.7M N/A $105.0M 45/100
Sutro Biopharma, Inc. STRO FY2025 $102.5M -$191.1M N/A $144.8M 42/100
enGene Therapeutics Inc. ENGN FY2025 N/A -$117.3M N/A $117.9M —
MacroGenics, Inc. MGNX FY2025 $149.5M -$74.6M -49.9% $126.5M 59/100
Compass Therapeutics, Inc. CMPX FY2025 $0 -$66.5M N/A $122.2M —
Zentalis Pharmaceuticals, Inc. ZNTL FY2025 $0 -$137.1M N/A $133.6M —

Frequently Asked Questions

Innate Pharma S.A. (IPHA) reported $10.6M in total revenue for fiscal year 2025. This represents a -55.2% change in EUR terms compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Innate Pharma S.A. (IPHA) revenue declined by 55.2% year-over-year in EUR, the currency it reports in. Translated at each year’s own exchange rate, it went from $20.8M to $10.6M in fiscal year 2025.

No, Innate Pharma S.A. (IPHA) reported a net loss of $57.7M in fiscal year 2025.

Innate Pharma S.A. (IPHA) reported diluted earnings per share of -$0.65 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Innate Pharma S.A. (IPHA) had EBITDA of -$61.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Innate Pharma S.A. (IPHA) recorded an outflow of $62.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Innate Pharma S.A. (IPHA) recorded an outflow of $61.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Innate Pharma S.A. (IPHA) had $73.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Innate Pharma S.A. (IPHA) invested $164K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Innate Pharma S.A. (IPHA) invested $51.2M in research and development during fiscal year 2025.

Innate Pharma S.A. (IPHA) had 94M shares outstanding as of fiscal year 2025.

Innate Pharma S.A. (IPHA) had a current ratio of 1.27 as of fiscal year 2025, which is considered adequate.

Innate Pharma S.A. (IPHA) had a return on assets of -78.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Innate Pharma S.A. (IPHA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $105.0M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Innate Pharma S.A. (IPHA) trades at 9.9x sales, its market capitalization divided by $10.6M revenue, FY2025. The market capitalization is $105.0M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Innate Pharma S.A. (IPHA) has negative shareholder equity of -$25.5M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Innate Pharma S.A. (IPHA) has a Piotroski F-Score of 0 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Innate Pharma S.A. (IPHA) reported a net loss of $57.7M while operations used $61.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Innate Pharma S.A. (IPHA) reported an operating loss of $63.4M against $516K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Innate Pharma S.A. (IPHA) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Innate Pharma S.A. it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top